cyclopharm
Nuclear Medicine

Cyclopharm Limited

A profitable and growing market leader
in nuclear medical imaging and lung healthcare

2016 Annual General Meeting

11 May 2016

cyclopharm
Nuclear Medicine

2016 AGM

Chairman's Address

Vanda Gould

Our Strategy

cyclopharm
Nuclear Medicine

CYC has clear strategy to leverage our position as a leading player in the global nuclear medicine imaging market and lung health space to expand the use of our proprietary products and introduce new innovative technology.

We will do this by:

1. **Attaining approval to distribute Technegas in the USA**

2. **Expanding the use of Technegas beyond the traditional diagnosis of Pulmonary Embolism into significantly larger applications such as $COPD_1$ and Asthma, Lung Cancer and Pulmonary Hypertension for both diagnosis and patient management.**

3. **Identifying, developing and commercialising complementary innovative technology such as Ultralute™**

4. **Leveraging our core global regulatory strengths, fiscal discipline, strong balance sheet and well developed expertise in nuclear medicine and pulmonary healthcare to seek out complementary technologies and businesses**

1. COPD-Chronic Obstructive Pulmonary Disease

cyclopharm
Nuclear Medicine

2016 AGM

Managing Director's Review

James McBrayer

- Company Overview
- Introduction
- 2015 Highlights
- 2015 Financial Results and Performance
- Product Overview and Growth Opportunities
  - — Technegas
  - — Untralute
- 2016 Strategic Priorities and Outlook

CYC's 10 Fast Facts

cyclopharm
Nuclear Medicine

1. Technegas is a well established proprietary world leader in functional lung ventilation imaging technology with major revenues generated by single patient consumables
2. Technegas is sold in 55 countries with significant expansion opportunities in the USA following USFDA approval of Phase 3 clinical trials
3. Chronic Obstructive Pulmonary Disease (COPD) and Asthma represent tremendous opportunity for substantial growth world wide
4. Ultralute™, a new innovative technology with global application, to be commercialised in 2016
5. Ultralute™ technology is a platform for additional product development
6. Stable management and workforce
7. Another year of solid financial results in FY 2015 with strong foundations for growth: $12.58m sales; $4.79m NPAT (Including $2.1m insurance settlement net proceeds), and $4.15m operating cash flow ($2.74m from Technegas). Strong balance sheet with $6.44m in cash at 31 December 2015.

An Australian Biotech that is:

8. Profitable ,Generating cash & paying dividends.
9. Net cash on the balance sheet to fund growth and
10. Set to leverage tangible major growth opportunities.

Introduction

In 2015 Cyclopharm made significant progress on our strategy to deliver a substantial increase in shareholder value through the global manufacture and supply of innovative nuclear medicine technologies

- **Well established, profitable and fiscally disciplined biotech**, with recurring cash flows predominantly generated from a line of consumable products
  - Second year of consecutive record revenue and profit
- **Technegas product is the world leader** in the functional lung ventilation imaging
  - Actively endorsed by global industry bodies, including the European Association of Nuclear Medicine
- **Near term growth opportunities** include:
  - Attaining USA approval for Technegas targeted for H2 2018
  - Expanding the use of Technegas beyond Pulmonary Embolism to include COPD, Asthma, Pulmonary Hypertension and Lung Cancer
  - Introducing new technologies to include Ultralute™ in H2 2016
- **Strong financial position** and cash flows funding:
  - Market growth and R&D initiatives
  - Payment of inaugural dividends

Our Business

cyclopharm Nuclear Medicine

cyclomedica Nuclear Medicine (Technegas)	Manufacturer and distributor of pulmonary ventilation imaging devices and equipment	• Track record of growing revenue, profits and cash flows • FDA trials for sales in US progressing • Preliminary China trials indicate that Technegas can be an effective tool to diagnose and monitor COPD
ultralute	Technology which extends the life of nuclear isotopes by up to 50%	• Fine tuning in 2016 • IP Secured • First sales expected in late 2016 • Strong International interest
MMI Macquarie Medical Imaging	Joint Venture with Macquarie University Hospital	• Growth tied to hospital ramp-up • Now EBIT positive
cyclopet Nuclear Medicine (Facility)	Cyclotron business (suspended operations in April 2014)	• Insurance settlement reached in December 2015 with net proceeds of $2.1m • Facility's medium to long term status under evaluation

2015 Highlights

cyclopharm
Nuclear Medicine

- **Record sales of $12.6 million**
- **Record Technegas division operating EBITDA of $2.3 million**
- **Record NPAT $4.8 million**
- **Payment of maiden dividends**
- **Strong cashflow from operations significantly strengthened the balance sheet, with cash reserves at year end totalling $6.4 million**
- **USFDA reengaged to leverage a faster and less costly path to approval with USA partnership under final negotiations**
- **Preliminary results of trials in China show Technegas can be an effective tool used to diagnose and monitor COPD**
- **Ultralute™ – Patent protection secured and commercialisation advanced**
- **New Generation Technegas Generator project takes shape**

2015 Financial Results & Performance

cyclopharm Nuclear Medicine

Year ended 31 December ($000's)	**2015**	**2014**
Underlying Results[1]:		
Revenue	**12,583**	**12,047**
Technegas EBITDA	2,980	2,638
Cyclopet EBITDA	(138)	(266)
Underlying EBITDA	**2,842**	**1,822**
Depreciation and amortisation	(144)	(266)
Underlying EBIT	**2,698**	**1,556**
Reported EBIT	4,115	3,578
Interest	(25)	(107)
Tax benefit	703	595
Reported NPAT	4,793	4,066
Reported Basic EPS (cents)	8.2	7.0
Dividends per share (cents)	1.0	0.0

- **Technegas continues to perform strongly**
- **Price increases and cost reduction initiatives drove improved gross margins**
- **Operating cash flow of $4.2m in line with reported NPAT – assisted by a net insurance settlement of $2.1m**
- **Cyclopet losses minimised due to suspension of operations**

1. **Underlying Results represent results from the Technegas Division excluding one off items (Insurance/Litigation settlement and costs), CLSA deposit**, FDA expenses and MMI equity accounted earnings.

Technegas – Expanding the Global footprint

cyclopharm
Nuclear Medicine

- **Technegas sold in 55 countries**
  - **Europe is the largest regional market for Technegas**
  - **In 2014 Canada became largest country market for Technegas surpassing France**
- **Over 3,500,000 patient studies since 1986**
- **1,500 Technegas generators sold globally**
- **Expanding operations in North America pending clinical trial and approval of United States FDA**
- **Expanding the use of Technegas targeting COPD with trials being finalised in China**
- **Expansion of clinical development program in 2016**
- **Patent protection until 2026 with optionality for extension**





	2010	2011	2012	2013	2014	2015
Asia Pacific	$2,182	$2,018	$1,795	$2,348	$2,376	$2,470
N & S America	$1,689	$1,814	$2,201	$1,857	$2,342	$2,227
Europe & Middle East	$5,572	$5,646	$5,372	$6,252	$6,772	$7,812
AUD:EURO	0.688	0.743	0.801	0.735	0.683	0.679

Technegas – USFDA clinical trial program

cyclopharm Nuclear Medicine

USA Market Size:

- Half the world's nuclear medicine departments are in the USA
- USA represents a potential base Pulmonary Embolism market of 480,000 patients per annum. (Current Rest of the World volumes = 200,000 patients per annum)

Study Specifics:

- Non-inferiority structural ventilation study comparing Xe133 vs. Technegas
- Pathway to approval requires a two part study (CYC 010 & CYC009)
  - CYC 010 – Establishes the Inter and Intra reader variability for Xe133
  - CYC 009 - Compares Xe133 with Technegas requiring patient recruitment
- "All Comers" protocol to eliminate previous obstacles in patient recruitment

Total estimated trial cost = less than $7 million USD

- Assumes <300 patient study at 10 clinical sites
- CYC has decided at this stage to independently proceed in funding the trial

Ultralute™

cyclopharm
Nuclear Medicine

Product overview

- Disruptive Technology – changes 60 years of how radiopharmaceuticals are manufactured
- Extends the effective use of Mo99 generator up to 50%
- Each cartridge consumable designed for a maximum of 10 uses
- Patents secured in 2014
- Will be designated as laboratory equipment
- Market introduction represents a base platform for additional applications
- Product launch was in late 2015 with revenues commencing H2 2016

Technology features

- Enables a user to extend the usable life of a Mo99 Generator
- Allows the user to purchase a smaller Mo99 Generator
- Provides greater flexibility in manufacturing products
- Provides a saving of between 30% to 40% in the cost of Tc-99m
- Enhances radiolabelling efficiency and imaging quality
- Purifies contaminants from the Tc99m eluate
- Provides a platform for further product development

Ultralute™ Generation overview

cyclopharm Nuclear Medicine

GEN 1
- **Designed for the end user application**
- **Introduced to market Q4 2015 with revenues commencing H2 2016**

GEN 2
- **Designed for radiopharmacy application**
- **Development will commence in 2015 for 2017 market introduction**

GEN 3
- **Designed for n,Gamma reactions**
- **Ultralute technology ideal for concentrating low specific activity generated by n.Gamma Mo99 production**
- **Discussions with Mo99 manufacturers commenced in 2015**

- There are 4,000 Mo99 generators sold worldwide **<u>each week</u>**.
- Approximately 50% are sold to Radiopharmacies with the remaining sold directly to end users in hospitals and clinics

Molybdenum Manufacturing and Supply Chain

2016 Strategic Priorities and Outlook

cyclopharm
Nuclear Medicine

Strategic Goals & Guidance	Activity	Timeframe
United States FDA approval	• Proceed on an independent path to USA market approval • Commence USFDA clinical trials • Relocate the Cyclopharm manufacturing premises and commence USFDA manufacturing compliance readiness	Q2 2016 Q2 2016 Q3 2016
Indication Expansion	• Implement clinical marketing strategy targeting the referring physicians • Complete COPD Trial in China and publish results	Q2 2016 Q4 2016
New Product – Ultralute™	• First sales of Ultralute™	H2 2016
Expand Product & Service Offering	• Identify and evaluate business prospects targeting growth, product extension, diversification, accretion and enhanced returns	Ongoing
Full Year Guidance	• Underlying ongoing operations financial performance expected to be consistent with that of 2015 • Dividend program expected to be maintained • Profits impacted significantly due to USFDA clinical trial expenses	FY 2016

cyclopharm
Nuclear Medicine

2016 AGM

Formal Business

Vanda Gould

2016 AGM – Formal Business

cyclopharm
Nuclear Medicine

Resolution	Business	For	Against	Abstain	Proxy's Discretion
1	Remuneration report	46,274,021*	1,865	94,595	38,000
2	Re-election of Vanda Gould	43,597,848*	2,772,633	-	38,000
3	Renewal of share buy-back capacity	46,406,741*	1,277	463	-
Contingent business					
4	Board spill meeting	24,188	46,337,734^	8,559	38,000

*Includes Open Useable Proxies that have instructed the Chairman to vote on their behalf and have voted in favour of the resolution.

^Includes Open Useable Proxies that have instructed the Chairman to vote on their behalf and have voted against the resolution.

Cyclopharm Limited

Appendix Section

- Cyclopharm History
- Technegas 2015 Financial Results
- Growth Opportunities and Key Performance Indicators
- Technegas
- Ultralute
- MMI
- Disclaimer

Our History

cyclopharm
Nuclear Medicine

1984 Technegas discovered and commercialised

1988 Technegas enters European market

1992 European markets established

1996 Technegas registered in the EU as a drug

2000 Vita Life Sciences acquires Tetley Medical

2003 Canadian regulatory approval attained for Technegas

2001 USFDA program initiated for Technegas

2007 Cyclopharm Ltd listed on the ASX

2007 Technegas Plus generator launched

2009 Entered molecular imaging market & establishes MMI imaging JV

2013 Ultralute™ technology established

2015 Maiden Dividend. Ultralute™ launched

1985 1995 2000 2005 2010 2015 2016

cyclomedica Nuclear Medicine

cyclopharm

MMI MACQUARIE MEDICAL IMAGING

ultralute

Technegas
FY15 Performance

cyclopharm
Nuclear Medicine

Second consecutive year of record results

Year ended 31 December ($000's)	**2015**	**Change**	**2014**	**Change**	**2013**
Technegas Results:					
Sales Revenue					
PAS	10,145	▲ 8.1%	9,384	▲ 9.3%	8,583
Generators/service	2,363	▲ 12.2%	2,106	▲ 12.4%	1,874
Total Sales	**12,508**	▲ 8.9%	**11,490**	▲ 9.9%	**10,457**
Underlying EBITDA	**2,980**	▲ 13.0%	**2,638**	▲ 17.5%	**2,246**
Underlying EBITDA Margin	23.8%	▲ 0.8%	23.0%	▲ 1.5%	21.5%
FDA Expenses	(686)	▲ 43.5%	(478)	–	(478)
EBITDA	2,294	▲ 6.2%	2,160	▲ 22.2%	1,767
D&A	(137)	▼ 38.6%	(223)	–	(220)
EBIT	**2,157**	▲ 11.4%	**1,937**	▲ 25.2%	**1,547**
EBIT Margin	17.2%	▲ 0.3%	16.9%	▲ 2.1%	14.8%

- **Another record financial result in FY15**
- **PAS margins enhanced by improved local prices in Asia and Latin America**
- **Strong financial performance supports ongoing investment in R&D and costs associated with expansion into new markets**

Underlying Results represent results from the Technegas Division excluding one off items (Insurance/Litigation settlement and costs + impairment expense), CLSA deposit, FDA expenses and MMI equity accounted earnings.

Group Balance Sheet

Strong financial position

Year ended 31 December ($000's)	**2015**	**2014**
Cash	6,445	3,268
Other current assets	6,653	5,582
Non-current Assets	3,443	2,111
Total Assets	**16,541**	**10,961**
Current Liabilities	3,176	2,874
Borrowings	197	246
Non-current Liabilities	66	85
Total Liabilities	**3,439**	**3,205**
Net Assets	**13,102**	**7,756**

- **Improved cash position driven by strong cash flows from operations**
- **Capacity to fund growth initiatives and ongoing R&D**
- **The medium to long term future of the Cyclopet facility to include divestment is under consideration**
- **Debt free – Mortgage Debt retired in March 2016**

Cash Flow

cyclopharm
Nuclear Medicine

Growing cash generation

Year ended 31 December	**2015**	**2014**	**2013**
Operating Activities	4,154,834	4,468,780	1,185,110
Investing Activities	(651,654)	(238,756)	(1,209,113)
Financing Activities	(326,664)	(2,171,525)	(1,207,588)
Net Inc /(Dec) in Cash	3,176,516	2,058,499	1,231,591
Opening Cash	3,268,425	1,220,646	2,346,556
Foreign Exchange	54	(10,420)	105,681
Closing Cash	6,444,995	3,268,425	1,220,646
Other Income in Operating Activities	2,104,689	2,650,000	–
Payments for Deferred Expenditure in Investing Activities	(639,242)	(279,319)	(485,616)
Repayment of Bank Borrowings in Financing Activities	(48,355)	(2,171,255)	(1,204,310)

- **Strong cash reserves available to fund near to medium term growth opportunities**
- **Investment Activities in 2015 included FDA, Ultralute & Technegas product development**
- **Significant one-off cash upside in 2014 ($2.65m) from litigation mediation and in 2015 ($2.10m) from an insurance settlement**
- **Majority of underlying cash flow in 2015 was generated by Technegas ($2.74m)**
- **Relocation expense of $500k expected in 2016**
- **Dublin facility mortgage (€128k) retired in March 2016**

Growth Opportunities and Key Performance Indicators

cyclopharm Nuclear Medicine

Technegas	
USA	• The USA represents the single largest market with half of the world's nuclear medicine departments located there • Existing market for PE in the USA equates to ~480,000 patients per annum • First priority following USFDA approval is to repeat our Canadian experience by replacing the Xe133 market valued at $47m USD
Currency	< 15% of revenues are $AUD related; Currently > 60 % of Technegas revenues linked to Euro.
Seasonality	Historically 2H revenues are stronger due to higher procedures volume during northern hemisphere winters
Pricing & Product Margins	In 2015 the average selling price for PAS=$52.02 AUD & Technegas Generators = $27.6k AUD. Despite downward pressure on healthcare products globally, Technegas has been able to achieve price increases. Consolidated GM of 80.6% in 2015 made up of PAS, the profitability engine room, accounting for 81% of total Technegas revenues.
Sales Volumes	PAS boxes sold in 2015= 3,901equating to 195,050 patient studies Technegas generators continue to average 50-60 units per year
Competitive Products	• Xe133 has been eliminated from the Canadian market with the introduction of Technegas. Xe133 only used in the USA is a $USD 47M product in 2015 • Kr89 – excellent imaging properties. Only available in a few countries due to limited availability and high cost • DTPA in low patient volume sites continue where Technegas is available. Used in the USA off-label • CTPA continues to dominate the PE space; however concerns with high CTPA radiation dose and improved nuclear medicine imaging techniques are bringing referrers back to nuclear medicine VQ imaging
Intellectual Property	TechnegasPlus Generator patented until 2026 A new generation of Technegas generators is under development with the goal to extend patent protection
Clinical Indications	Primarily used for PE. Also used in preplanning and post surgical evaluation for lung reduction intervention The incidence of COPD is 30x that of PE. Furthermore, COPD represents an opportunity for ongoing patient management
Distribution	Cyclopharm continues to evaluate the effectiveness of Distributors/Agents/Partnerships/Independent
Facility Relocation	After 20 years of tenancy, ANSTO has notified Cyclopharm that our lease will not be renewed. The cost of relocation will have an impact in 2016 with an ongoing increase in facility costs likely.

Growth Opportunities and Key Performance Indicators

cyclopharm Nuclear Medicine

Ultralute	
Market Penetration	• Europe targeted as the primary market to launch due to the highest concentration of end user Mo99 generators in the world • 1st Generation targeted for launch in Germany at the EANM in October with initial sales to follow H2 2016
Margins	Product launch estimates 50% GM with margin improvement expected from leveraging volume growth
Product Development	• 1st Generation targeting end users in hospitals and clinics to be commercialised in 2016 • 2nd Generations targeted for Radiopharmacy will be introduced in 2017
Other Applications	Discussions underway with interested parties for extended applications with other isotopes

MMI	
Revenue	Volumes closely aligned with the hospital. Continued double digit growth expected per annum in the foreseeable future
Profitability	EBITDA positive as of mid CY 2014
MRI Licensing	Significant increase in profitability if Government funded MRI licensing is achieved

Cyclopet	
Molecular Imaging	Following competition from government owned enterprises, Cyclopharm's Board decided to suspend commercial operations. Subsequent to this decision the company successfully mediated an outcome that resulted in ANSTO paying $2.65M to Cyclopharm. Cyclopharm has no immediate intention of re-entering this market under the current competitive landscape.
Facility	Fully written off. Discussions underway relating to the long term to include disposal of the facility

Technegas Volume – Generators and PAS

cyclopharm Nuclear Medicine

Organic growth in the majority of markets



	2010	2011	2012	2013	2014	2015
Asia Pacific	$2,182	$2,018	$1,795	$2,348	$2,376	$2,470
N & S America	$1,689	$1,814	$2,201	$1,857	$2,342	$2,227
Europe & Middle East	$5,572	$5,646	$5,372	$6,252	$6,772	$7,812
AUD:EURO	0.688	0.743	0.801	0.735	0.683	0.679



- **Europe remains our largest single country market for Technegas**
- **France volumes rebounded in second half 2015 as advised**
- **Canada is our largest single country market with 12 consecutive years of PAS growth**
- **Canada represents a strong indicator of USA acceptance and Xe133 displacement**

Technegas – Global Indication Expansion

cyclopharm Nuclear Medicine

Targeting Chronic Obstructive Pulmonary Disease (COPD) market

Evaluating the effectiveness of Technegas in early detection of COPD and the presence of the comorbidities associated with the disease

Market Size:

- 30x the size of total PE market
- 65m people have moderate to severe COPD
- Estimates show that COPD becomes by 2030 will be the third leading cause of death

Timeline:

- Q2 2016 China trial recruitment completed
- Q4 2016 Results published at the Asian Pacific Society of Respirology Congress
- Plans to extend COPD initiative to additional markets including in Canada, South Africa, Australia and several European countries

China Study Specifics:

- Patient size: 120 patients
- Total cost = <$400K

Additional indication and applications – Asthma, Lung Reduction and CTEPH*

Technegas can provide the clinician the ability to visualise and quantify lung ventilation by region. No other diagnostic tool can provide consistent, accurate and reliable functional imaging in comparison.

Cyclopharm will leverage this market advantage in 2016 by initiating a clinical program targeting Technegas indication expansion to include:

Asthma

- 334 million people globally

Lung Reduction Intervention

- Application in determining ventilation pre and post lung reduction intervention

Chronic Thromboembolic Pulmonary Hypertension

- Ventilation/Perfusion imaging is the recommended
- Up to 40 million people globally

* CTEPH = Chronic Thromboembolic Pulmonary Hypertension

Technegas
Indication expansion – COPD

cyclopharm
Nuclear Medicine

The Global incidence of Chronic Obstructive Pulmonary Disease (COPD) is 30x greater than that of Pulmonary Embolism (PE)

It is estimated that by 2020, COPD will be the 4th highest cause of death globally. By 2030 COPD will be the 3rd highest cause of death globally.

Cyclopharm is undertaking a trial in China to assess the use of Technegas for the diagnosis and management of COPD

- Patient enrolment concluded in April 2016
- Preliminary research with Technegas suggests early detection than traditional Spirometry with 3 abstracts presented at the 2015 Asia Pacific Society of Respirology conference in December
- Spirometry – a basic measurement of forced air volume provides no underlying pathophysiology and required significant disease progression to diagnose

Expanding the use of Technegas from Pulmonary Embolism (PE) diagnosis to COPD would represent significant expansion of the market size

- In China, at any time more than 56.6 million people in China have COPD
- According to the Lancet 2008, it is predicted that China will see 65 million deaths from COPD and 18 million deaths from lung cancer between 2003 and 2033

Key drivers of the Chinese COPD market include:

- China is the greatest producer and user of tobacco in the world*
- Rapidly Aging Population
- High use of biomass burning at home for cooking
- Elevated incidence of post-pulmonary tuberculosis
- Poor air quality in metropolitan areas

*Fang X et al. Chest 2011; 139: 920-929

Ultralute™
Targeting direct users of Mo99

cyclopharm
Nuclear Medicine

- Ultralute™ v1 is targeted at the clinical end-user market that sources Mo99 Generators directly from manufacturers
- The European Mo99 generator market is completely Direct
- Ultralute registration in the EU has been determined to be a laboratory apparatus
- The largest single market for Mo99 generators in Europe is Germany
- Ultralute™ v2 is being developed for the Radiopharmacy user market

Macquarie Medical Imaging

cyclopharm Nuclear Medicine

MMI MACQUARIE MEDICAL IMAGING

- Joint venture with:
  - 50% Alfred Health Solutions
  - 30% Macquarie University
  - 20% Cyclopharm
- Comprehensive suite of imaging modalities
- State of the art research platform
- Growth and profitability linked to ramp-up of Macquarie University Hospital
- EBIT positive since 2014
- Sales revenue increased 5% in 2015 as outpatient initiatives implemented at Macquarie University Hospital take effect

CT

MRI

PET

Cardiac CT

Ultra-sound

SPECT

Disclaimer

Certain views expressed here contain information derived from publicly available sources that have not been independently verified.

The presentation include certain statements, estimates and projections with respect to the anticipated future financial performance of Cyclopharm Limited and as to the markets for the company's products. Such statements, estimates and projections reflect various assumptions made by the directors concerning anticipated results, which assumptions may or may not prove to be correct. Cyclopharm Limited has not sought independent verification of information in this presentation..

While the directors believe they have reasonable grounds for each of the statements, estimates and projections and all care has been taken in the preparation, no representation or warranty, express or implied, is given as to the accuracy, completeness or correctness, likelihood of achievement or reasonableness of statements, estimates and projections contained in this presentation. Such statements, estimates and projections are by their nature subject to significant uncertainties, contingencies and assumptions.

To the maximum extent permitted by law, none of the Cyclopharm Limited, its directors, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of information contained in this presentation.

All references to dollars unless otherwise specified are to Australian dollars.

Corporate Head Office
Cyclopharm Limited
Building 75 Business & Technology Park
New Illawarra Road
Lucas Heights NSW 2234 Australia
PO Box 350, Menai Central
NSW 2234 Australia
T: +61 (2) 9541 0411
F: +61 (2) 9543 0960

Enquiries
E: enquiries@Cyclopharm.com.au

Share Registry
RB Registries
Level 29 Suncorp Place
259 George Street
Sydney NSW 2000
T: +61 (2) 9032 3000
F: +61 (2) 9251 1275

.